McKesson recalls Inflectra (infliximab-dyyb)
- Published
- 5 Feb 2025
- Units affected
- 192 vials
- Agency
- FDA
- Country
- United States
The hazard
CGMP Deviations: Product intended for quarantine was inadvertently distributed.
Classification: Class II — this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.
What to do
Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.
- Check the lot number on the box or bottle.
- Talk to your pharmacist or doctor before stopping any prescribed medicine.
- Return the product to the pharmacy for safe disposal.
Product details
Inflectra (infliximab-dyyb), For injection, 100mg per vial, packaged in 10 mL single-dose vial, Rx only, Mfd by: CELLTRION, INC, Dist. by: Pfizer Labs, Division of Pfizer Inc., New York, NY 10001, NDC 0069-0809-01
- Brand / company
- McKesson
- Codes / lots
- Lot# 04647349, Exp Date 5/31/2029
- Distribution
- Nationwide USA
- Recall status
- Ongoing
Source: U.S. Food and Drug Administration, published 5 Feb 2025. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.